Elixir Pharmaceuticals

Pioneering the future of metabolic disease treatment by harnessing genetic interactions to combat aging and associated diseases.

Founded 1999 Series D Total: $98.50M Biotechnology, Pharmaceutical

Elixir Pharmaceuticals is a biotechnology and pharmaceutical company founded in 1999 with a mission to revolutionize the treatment of metabolic diseases. Their slogan "Pioneering the future of metabolic disease treatment by harnessing genetic interactions to combat aging and associated diseases" encapsulates their innovative approach. The company focuses on discovering, developing, and commercializing treatments for conditions like diabetes and obesity. They have gained recognition for identifying crucial interactions between specific genes and enzymes that can potentially slow down the aging process. Elixir Pharmaceuticals is actively working on developing compounds to stimulate these interactions, aiming to target a wide range of age-related diseases, including metabolic conditions. In May 2009, Elixir Pharmaceuticals secured a significant $12.00M Series D investment led by notable investors including Arch Venture Partners, MPM Capital, Omega Funds, Oxford Bioscience Partners, and Physic Ventures. This substantial support underscores the confidence that prominent venture capital firms have in the company's vision and potential. Elixir Pharmaceuticals' innovative approach to addressing age-related diseases through genetic interactions positions them as a compelling player in the biotechnology and pharmaceutical industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Series D	$12.00M	5	Arch Venture Partners, MPM Capital +3	19 May 2009
Debt Financing	$15.00M	1	Hercules Capital	27 Nov 2006
Series C	$31.00M	4	Arch Venture Partners, Hercules Capital +2	27 Nov 2006
Series B	$40.50M	-		13 Oct 2003

Funding Stage

Amount

Investors

Lead Investors

Date

Series D

$12.00M

Arch Venture Partners, MPM Capital +3

19 May 2009

Debt Financing

$15.00M

Hercules Capital

27 Nov 2006

Series C

$31.00M

Arch Venture Partners, Hercules Capital +2

27 Nov 2006

Series B

$40.50M

13 Oct 2003

FAQ About Elixir Pharmaceuticals

Pioneering the future of metabolic disease treatment by harnessing genetic interactions to combat aging and associated diseases.

Elixir Pharmaceuticals was founded in 1999.

Elixir Pharmaceuticals operates in Biotechnology and Pharmaceutical. Its work centres on Pharmaceuticals, Metabolic disease treatment, Genetic interactions and Aging research.

Elixir Pharmaceuticals has completed 4 funding rounds, raising a total of $98.50M. The latest funding stage is Series D.

Top alternatives and competitors to Elixir Pharmaceuticals include Sirtris Pharmaceuticals, Gero, Dicerna Pharmaceuticals, Revel Pharmaceuticals, Ousia Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Elixir Pharmaceuticals and Sirtris Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Elixir Pharmaceuticals

Funding Rounds & Investors (4)

Elixir Pharmaceuticals Alternatives & Competitors

FAQ About Elixir Pharmaceuticals